Freestone Grove Partners’s Centessa Pharmaceuticals CNTA Stock Holding History

Freestone Grove Partners’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.34M	Buy	+109,327	New	+$2.8M	0.03%	332

Other funds holding CNTA

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

IVLAV

Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Freestone Grove Partners's CNTA Position: Q1 2026 in Review

Freestone Grove Partners opened a new position in Centessa Pharmaceuticals (CNTA) in Q1 2026: 109,327 shares worth $4.34M. The stake represents 0.03% of the portfolio and ranks #332 among its holdings.

161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

Freestone Grove Partners held 109,327 shares of Centessa Pharmaceuticals worth $4.34M as of Q1 2026.
Centessa Pharmaceuticals was a new Freestone Grove Partners position in Q1 2026.
Centessa Pharmaceuticals made up 0.03% of Freestone Grove Partners's portfolio in Q1 2026, its #332 holding.
161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.